Search

344 Result(s)
Sort by

Collaborating for social impact

Collaborating for social impact

Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
The GPP Charter

The GPP Charter

The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
The GPP Forum

The GPP Forum

The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Partnering in Retinal Health

Partnering in Retinal Health

Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Animal Health Collaboration with Novozymes

Animal Health Collaboration with Novozymes

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Cardiometabolic Diseases

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.